Shareholders at Datalink Corporation (NASDAQ:DTLK) are scheduled to vote at a special meeting on the company's proposed merger with Insight Enterprises. Datalink closed yesterday just a penny above the buyout price of $11.25.
There's also an annual meeting for Cantel Medical Corp. (NYSE:CMN) to keep a watch on.
Athenahealth (NASDAQ:ATHN) initiated with Hold rating by Stifel Nicolaus.
Juno Therapeutics (NASDAQ:JUNO) initiated with Sell rating and $23 (15% downside risk) price target by BTIG Research. Initiated coverage on Kite Pharma (NASDAQ:KITE) with Neutral rating.
Gemphire Therapeutics (Pending:GEMP) initiated with Buy rating and $17 (26% upside) price target by Canaccord Genuity. Initiated with Outperform rating and $25 (86% upside) price target by RBC Capital.
Galapagos NV (NASDAQ:GLPG) initiated with Buy rating and $64 (18% upside) price target by Janney Capital.
Sophiris Bio (NASDAQ:SPHS) initiated with Overweight rating and $7 (138% upside) price target by Piper Jaffray.
Cantel Medical (NYSE:CMN) initiated with Buy rating and $83 (9% upside) price target by Benchmark.
Recro Pharma (NASDAQ:REPH) initiated with Buy rating and $21 (122% upside) price target by Janney Montgomery Scott.
Theravance Biopharma (NASDAQ:TBPH) initiated with Buy rating and $41 (42% upside) price target by Evercore ISI.
Intuitive Surgical (NASDAQ:ISRG) initiated with Outperform rating by Raymond James.
Cantel Medical (CMN -0.3%) acquires the Sterility Assurance Monitoring Products division of North American Science Associates (NAMSA) for $13.5M in cash. The group, which generated $5.7M in sales last year, is comprised of a broad suite of biological and chemical indicators that are used to accurately monitor the effectiveness of sterilization processes. Cantel will fold the business into its Crosstex line in its Healthcare Disposables segment.
The transaction should be neutral to GAAP earnings and slightly accretive to non-GAAP earnings in fiscal 2016 (year end July 31) and accretive to both afterward. The deal should close in fiscal Q3.